FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities

Fibroblast growth factor 5 (FGF5) is widely expressed in embryonic but scarcely in adult tissues. Here we report simultaneous overexpression of FGF5 and its predominant high-affinity receptor (FGFR1 IIIc) in astrocytic brain tumour specimens (N=49) and cell cultures (N=49). The levels of both ligand and receptor increased with enhanced malignancy in vivo and in vitro. Furthermore, secreted FGF5 protein was generally present in the supernatants of glioblastoma (GBM) cells. siRNA-mediated FGF5 downmodulation reduced moderately but significantly GBM cell proliferation while recombinant FGF5 (rFGF5) increased this parameter preferentially in cell lines with low endogenous expression levels. Apoptosis induction by prolonged serum starvation was significantly prevented by rFGF5. Moreover, tumour cell migration was distinctly stimulated by rFGF5 but attenuated by FGF5 siRNA. Blockade of FGFR1-mediated signals by pharmacological FGFR inhibitors or a dominant-negative FGFR1 IIIc protein inhibited GBM cell proliferation and/or induced apoptotic cell death. Moreover, rFGF5 and supernatants of highly FGF5-positive GBM cell lines specifically stimulated proliferation, migration and tube formation of human umbilical vein endothelial cells. In summary, we demonstrate for the first time that FGF5 contributes to the malignant progression of human astrocytic brain tumours by both autocrine and paracrine effects.

[1]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[2]  M. Goldfarb,et al.  The human FGF-5 oncogene encodes a novel protein related to fibroblast growth factors , 1988, Molecular and cellular biology.

[3]  M. Goldfarb,et al.  Expression of the murine fibroblast growth factor 5 gene in the adult central nervous system. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Hardin,et al.  Biosynthesis of human fibroblast growth factor-5 , 1991, Molecular and cellular biology.

[5]  M. Goldfarb,et al.  Expression of the fibroblast growth factor-5 gene in the mouse embryo. , 1991, Development.

[6]  C. Cotman,et al.  Distribution of fibroblast growth factor 5 mRNA in the rat brain: an in situ hybridization study , 1993, Brain Research.

[7]  H. Thoenen,et al.  Evidence that fibroblast growth factor 5 is a major muscle-derived survival factor for cultured spinal motoneurons , 1993, Neuron.

[8]  R. Bjerkvig,et al.  Effects of EGF, BFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain‐tumour biopsies In Vitro , 1993, International journal of cancer.

[9]  G. Martin,et al.  FGF5 as a regulator of the hair growth cycle: Evidence from targeted and spontaneous mutations , 1994, Cell.

[10]  E. Castrén,et al.  Fibroblast Growth Factor‐5 Promotes Differentiation of Cultured Rat Septal Cholinergic and Raphe Serotonergic Neurons: Comparison with the Effects of Neurotrophins , 1994, The European journal of neuroscience.

[11]  J. Bruner,et al.  Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. , 1994, Cancer research.

[12]  C. MacArthur,et al.  Receptor Specificity of the Fibroblast Growth Factor Family* , 1996, The Journal of Biological Chemistry.

[13]  P. Maher,et al.  Nuclear localization of functional FGF receptor 1 in human astrocytes suggests a novel mechanism for growth factor action. , 1996, Brain research. Molecular brain research.

[14]  J. Smith,et al.  Fibroblast growth factors and their receptors. , 1997, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[15]  S. Coons,et al.  Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells , 1997, Oncogene.

[16]  J. Sundberg,et al.  Angora Mouse Mutation: Altered Hair Cycle, Follicular Dystrophy, Phenotypic Maintenance of Skin Grafts, and Changes in Keratin Expression , 1997, Veterinary pathology.

[17]  M. Korc,et al.  Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions , 1997, Oncogene.

[18]  R. Panek,et al.  In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. , 1998, The Journal of pharmacology and experimental therapeutics.

[19]  M. Kan,et al.  The heparan sulfate-fibroblast growth factor family: diversity of structure and function. , 1998, Progress in nucleic acid research and molecular biology.

[20]  G. Mills,et al.  Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. , 1998, Cancer research.

[21]  A. Komi,et al.  An Alternatively Spliced Fibroblast Growth Factor (FGF)-5 mRNA Is Abundant in Brain and Translates into a Partial Agonist/Antagonist for FGF-5 Neurotrophic Activity* , 1998, The Journal of Biological Chemistry.

[22]  J. Hanfelt,et al.  Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. , 1998, Cancer research.

[23]  T. Imamura,et al.  Localization of rat FGF-5 protein in skin macrophage-like cells and FGF-5S protein in hair follicle: possible involvement of two Fgf-5 gene products in hair growth cycle regulation. , 1998, The Journal of investigative dermatology.

[24]  C. Raffel Expression and Growth Stimulatory Effect of Fibroblast Growth Factor 9 in Human Brain Tumors , 1998 .

[25]  R. Jensen,et al.  Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. , 1998, Surgical neurology.

[26]  T. Mohr,et al.  Evidence for a role of FGF‐2 and FGF receptors in the proliferation of non‐small cell lung cancer cells , 1999, International journal of cancer.

[27]  T. Imamura,et al.  Dual-mode regulation of hair growth cycle by two Fgf-5 gene products. , 2000, The Journal of investigative dermatology.

[28]  K. Unsicker,et al.  Fibroblast growth factors‐5 and ‐9 distinctly regulate expression and function of the gap junction protein connexin43 in cultured astroglial cells from different brain regions , 2000, Glia.

[29]  G. Christofori,et al.  N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling , 2001, Nature Cell Biology.

[30]  Murray Korc,et al.  Expression of the IIIc variant of FGF receptor-1 confers mitogenic responsiveness to heparin and FGF-5 in TAKA-1 pancreatic ductal cells , 2001, International journal of gastrointestinal cancer.

[31]  J. Yang,et al.  Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. , 2001, Cancer research.

[32]  Koshi Matsumoto,et al.  Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas , 2002, Neurological research.

[33]  P. Rathjen,et al.  Transient pluripotent cell populations during primitive ectoderm formation: correlation of in vivo and in vitro pluripotent cell development. , 2002, Journal of cell science.

[34]  K. Unsicker,et al.  Functions of Fibroblast Growth Factor (FGF)-2 and FGF-5 in Astroglial Differentiation and Blood-Brain Barrier Permeability: Evidence from Mouse Mutants , 2003, The Journal of Neuroscience.

[35]  Souichi Yoshida,et al.  Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. , 2003, The Journal of clinical endocrinology and metabolism.

[36]  Bernhard Reuss,et al.  Fibroblast growth factors and their receptors in the central nervous system , 2003, Cell and Tissue Research.

[37]  W. Berger,et al.  Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications , 2005, Journal of Cancer Research and Clinical Oncology.

[38]  William Pao,et al.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  V. P. Eswarakumar,et al.  Cellular signaling by fibroblast growth factor receptors. , 2005, Cytokine & growth factor reviews.

[40]  A. Kyritsis,et al.  Mechanisms of angiogenesis in gliomas , 2006, Journal of Neuro-Oncology.

[41]  C. Dickson,et al.  Fibroblast growth factor signaling in tumorigenesis. , 2005, Cytokine & growth factor reviews.

[42]  M. Berger,et al.  Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas , 1994, Journal of Neuro-Oncology.

[43]  A. Gressner,et al.  Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells , 2005, Growth factors.

[44]  Petra Heffeter,et al.  Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). , 2006, Biochemical pharmacology.

[45]  C. Pirker,et al.  The major vault protein is responsive to and interferes with interferon-γ-mediated STAT1 signals , 2006, Journal of Cell Science.

[46]  C. Pirker,et al.  The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals. , 2006, Journal of cell science.

[47]  H. Bergmeister,et al.  Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT. , 2006, Cancer research.

[48]  A. Paetau,et al.  Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas , 2006, Molecular Cancer Research.

[49]  Gerhard Dürnberger,et al.  Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. , 2007, Blood.

[50]  S. Spiegl-Kreinecker,et al.  Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma , 2007, British Journal of Cancer.